Diagnosis and Severity Criteria for Sinusoidal Obstruction Syndrome/veno-occlusive Disease in Pediatric Patients: a New Classification from the European Society for Blood and Marrow Transplantation

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2017 Aug 1

PMID 28759025

Citations 111

Authors

S Corbacioglu

E Carreras

M Ansari

A Balduzzi

S Cesaro

J-H Dalle

F Dignan

B Gibson

T Guengoer

B Gruhn

A Lankester

F Locatelli

A Pagliuca

C Peters

P G Richardson

A S Schulz

P Sedlacek

J Stein

K-W Sykora

J Toporski

E Trigoso

K Vetteranta

J Wachowiak

E Wallhult

R Wynn

I Yaniv

A Yesilipek

M Mohty

P Bader

Affiliations

Soon will be listed here.

Abstract

The advances in hematopoietic cell transplantation (HCT) over the last decade have led to a transplant-related mortality below 15%. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication of HCT that belongs to a group of diseases increasingly identified as transplant-related, systemic endothelial diseases. In most cases, SOS/VOD resolves within weeks; however, severe SOS/VOD results in multi-organ dysfunction/failure with a mortality rate >80%. A timely diagnosis of SOS/VOD is of critical importance, given the availability of therapeutic options with favorable tolerability. Current diagnostic criteria are used for adults and children. However, over the last decade it has become clear that SOS/VOD is significantly different between the age groups in terms of incidence, genetic predisposition, clinical presentation, prevention, treatment and outcome. Improved understanding of SOS/VOD and the availability of effective treatment questions the use of the Baltimore and Seattle criteria for diagnosing SOS/VOD in children. The aim of this position paper is to propose new diagnostic and severity criteria for SOS/VOD in children on behalf of the European Society for Blood and Marrow Transplantation.

Citing Articles

Complement activation and vascular complications after pediatric allogeneic hematopoietic stem cell transplantation.

Leimi L, Vettenranta K, Meri S Sci Rep. 2025; 15(1):7073.

PMID: 40016347 PMC: 11868490. DOI: 10.1038/s41598-025-91455-5.

Defibrotide for the Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Paediatric Patients Who Did Not Receive Haematopoietic Stem Cell Transplantation: Case Reports of Patients From a German Academic Hospital.

Kleinschmidt K, Troeger A, Foll J, Hanafee-Alali T, Jakob M, Kramer S EJHaem. 2025; 6(1):e1094.

PMID: 39866932 PMC: 11756966. DOI: 10.1002/jha2.1094.

A Second Look: Retrospective Identification of Thrombotic Microangiopathy in Pediatric Stem Cell Transplant Patients With Veno-Occlusive Disease.

Rahim M, Nichols C, Althouse S, Rahrig A Pediatr Transplant. 2025; 29(1):e70003.

PMID: 39777832 PMC: 11707639. DOI: 10.1111/petr.70003.

Missing the mark(ers): circulating endothelial cells and endothelial-derived extracellular vesicles are elevated in sickle cell disease plasma.

Beckman J, Zhang P, Nguyen J, Hebbel R, Vercellotti G, Belcher J Front Immunol. 2025; 15():1493904.

PMID: 39776915 PMC: 11703723. DOI: 10.3389/fimmu.2024.1493904.

The EASIX score as a predictor of sinusoidal obstruction syndrome and nonrelapse mortality in paediatric patients receiving allogeneic haematopoietic stem cell transplantation.

Muratore E, Gambuti G, Leardini D, Baccelli F, Venturelli F, Larcinese L Bone Marrow Transplant. 2024; 60(3):346-352.

PMID: 39658654 PMC: 11893459. DOI: 10.1038/s41409-024-02489-8.

References

Qayed M, Chiang K, Ricketts R, Alazraki A, Tahvildari A, Haight A . Tandem stem cell rescue as consolidation therapy for high-risk neuroblastoma. Pediatr Blood Cancer. 2011; 58(3):448-52. DOI: 10.1002/pbc.23155. View

Elli M, Pinarli F, Dagdemir A, Acar S . Veno-occlusive disease of the liver in a child after chemotherapy for brain tumor. Pediatr Blood Cancer. 2005; 46(4):521-3. DOI: 10.1002/pbc.20338. View

Akil A, Zhang Q, Mumaw C, Raiker N, Yu J, Velez de Mendizabal N . Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2015; 21(10):1739-45. PMC: 4568166. DOI: 10.1016/j.bbmt.2015.07.004. View

Czauderna P, Katski K, Kowalczyk J, Kurylak A, LOPATKA B, Sawicz-Birkowska K . Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients. Eur J Pediatr Surg. 2001; 10(5):300-3. DOI: 10.1055/s-2008-1072380. View

Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J . On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol. 1993; 66(2):77-80. DOI: 10.1007/BF01695888. View

Norol F, Kuentz M, Cordonnier C, Beaujean F, Haiouin C, Vernant J . [Influence of clinical status on the efficacy of stored platelet transfusion]. Rev Fr Transfus Hemobiol. 1993; 36(5):427-37. DOI: 10.1016/s1140-4639(05)80155-8. View

Fan C, Crawford J . Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol. 2015; 4(4):332-46. PMC: 4298625. DOI: 10.1016/j.jceh.2014.10.002. View

McKoy J, Angelotta C, Bennett C, Tallman M, Wadleigh M, Evens A . Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2006; 31(5):599-604. DOI: 10.1016/j.leukres.2006.07.005. View

Sulis M, Bessmertny O, Granowetter L, Weiner M, Kelly K . Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma. J Pediatr Hematol Oncol. 2004; 26(12):843-6. View

10.

Huezo-Diaz Curtis P, Uppugunduri C, Muthukumaran J, Rezgui M, Peters C, Bader P . Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation. Pharmacogenomics J. 2016; 18(1):64-69. PMC: 5817388. DOI: 10.1038/tpj.2016.65. View

11.

Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A . Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012; 379(9823):1301-9. DOI: 10.1016/S0140-6736(11)61938-7. View

12.

Cheuk D, Wang P, Lee T, Chiang A, Ha S, Lau Y . Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007; 40(10):935-44. DOI: 10.1038/sj.bmt.1705835. View

13.

Mortele K, Van Vlierberghe H, Wiesner W, Ros P . Hepatic veno-occlusive disease: MRI findings. Abdom Imaging. 2002; 27(5):523-6. DOI: 10.1007/s00261-001-0097-5. View

14.

Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G . Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007; 13(3):307-14. DOI: 10.1016/j.bbmt.2006.10.026. View

15.

Richardson P, Elias A, Krishnan A, Wheeler C, Nath R, Hoppensteadt D . Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998; 92(3):737-44. View

16.

Veal G, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D . Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. Eur J Cancer. 2012; 48(16):3063-72. DOI: 10.1016/j.ejca.2012.05.020. View

17.

Corbacioglu S, Honig M, Lahr G, Stohr S, Berry G, Friedrich W . Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant. 2006; 38(8):547-53. DOI: 10.1038/sj.bmt.1705485. View

18.

Lee J, Gooley T, Bensinger W, Schiffman K, McDonald G . Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 1999; 5(5):306-15. DOI: 10.1016/s1083-8791(99)70006-6. View

19.

Nazemi K, Shen V, Finlay J, Boyett J, Kocak M, Lafond D . High Incidence of Veno-Occlusive Disease With Myeloablative Chemotherapy Following Craniospinal Irradiation in Children With Newly Diagnosed High-Risk CNS Embryonal Tumors: A Report From the Children's Oncology Group (CCG-99702). Pediatr Blood Cancer. 2016; 63(9):1563-70. PMC: 4955719. DOI: 10.1002/pbc.26074. View

20.

Iguchi A, Kobayashi R, Kaneda M, Kobayashi K . Plasma protein C is a useful clinical marker for hepatic veno-occlusive disease (VOD) in stem cell transplantation. Pediatr Blood Cancer. 2009; 54(3):437-43. DOI: 10.1002/pbc.22314. View